US Markets for Peripheral Stents Get AAA Rating

According to "US Markets for Peripheral Vascular Stents," a report recently published by the Medtech Insight division of Elsevier Business Intelligence, the peripheral vascular stent market yielded more than $1 billion in revenues in the US in 2009, and will continue to grow at an overall rate of 7.2% in coming years, with some product segments growing even faster. Stents for carotid arteries are expected to yield a 36.5% annual compound growth rate through 2014 and endovascular products for the repair of aortic aneurysms (AAA) will grow by 8.4%, according to the Medtech Insight report. AAA endografts accounted for 43.7% of peripheral vascular stent sales last year.

After three decades of dramatic innovation in coronary artery disease, peripheral vascular disease has moved up in the evolutionary chain. With the mature coronary artery space now offering low single-digit growth rates, medical device companies of all sizes are looking to the product opportunities in peripheral arterial disease, a market estimated to grow by 10 to 12% per year from its current level of $3 to $3.5 billion. Two major acquisitions in the space have underscored the opportunities. In January 2010, Medtronic PLC paid $350 million plus earn-outs to acquire Invatec SPA, which, beginning in peripheral vascular disease, captured the European market and is now bringing its strategy to the US. [See Deal] ( See "Invatec: Translating Global Success in Vascular Devices to the US Market," IN VIVO, October 2009Also see "Invatec: Translating Global Success in Vascular Devices to the US Market" - In Vivo, 1 October, 2009..) Five months later, Covidien Ltd. acquired ev3 Inc., a major presence in non-coronary percutaneous interventions with some 100 such products. [See Deal] The medical device industry has officially recognized that peripheral vascular disease is not an extension of interventional cardiology, but is in need of innovation directed at peripherally specific products. This recognition has extended beyond arterial disease to new markets opening up in venous disease. ( See,"Venous Device Companies Dig Deep," this issueAlso see "Vein Device Companies Dig Deeper " - Medtech Insight, 1 March, 2011..)

According to " US Markets for Peripheral Vascular Stents," a report recently published by the Medtech Insight division of Elsevier...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

European MedTech Keeps Calm Despite US Threats Of 30% Tariffs

 

MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”